Effect of Fish Oil on Atopic Dermatitis
A Randomized, Double-blinded Nutritional Study to Determine the Effect of a Concentrated Cetoleic Acid Fish Oil on Atopic Dermatitis
This study is testing if a fish oil supplement can help people with mild to moderate eczema improve their skin condition over six months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Møreforsking AS Academic / other |
| Locations | 1 site (Ålesund, Møre Og Romsdal) |
| Trial ID | NCT06194045 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of cetoleic acid, a long-chain monounsaturated fatty acid found in fish oil, on individuals with mild to moderate atopic dermatitis. Participants will be randomly assigned to receive either cetoleic-rich fish oil or a placebo for a duration of six months. The study aims to assess changes in skin condition and inflammation levels before, during, and after the intervention. By examining the lipid composition and microbiome changes, the research seeks to understand the potential benefits of cetoleic acid in managing atopic dermatitis.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 18-80 with a diagnosis of active mild to moderate atopic dermatitis.
Not a fit: Patients with known allergies to fish products or those with other skin diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new dietary approach to effectively manage and alleviate symptoms of atopic dermatitis.
How similar studies have performed: Previous studies have indicated an anti-inflammatory effect of cetoleic acid, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women and men 18-80 years of age. * Diagnosed with active mild to moderate atopic dermatitis with an EASI of 1.1- 21.0. * Willing to refrain from oil supplements (omega-3, borage, evening primrose, etc.) for 1 month before study begin (washout) and during the study * Willing to take the study supplement for 6 months Exclusion Criteria: * Known allergy to fish products * Subjects known to be pregnant or breast feeding * Subjects perceiving systemically administered medication for AD (other than topical) * Subjects with auto-immune diseases (except asthma and seasonal/perennial rhinitis) * Subjects with a diagnosis of other skin diseases
Where this trial is running
Ålesund, Møre Og Romsdal
- Helse Møre og Romsdal HF — Ålesund, Møre Og Romsdal, Norway (Recruiting)
Study contacts
- Principal investigator: Dag Arne Lihaug Hoff — Helse Møre og Romsdal HF
- Study coordinator: Lisa Kolden Midtbø, PhD
- Email: lisa.kolden.midtbo@moreforsking.no
- Phone: +47 70 11 16 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.